stents

Net clinical benefit of bivalirudin in STEMI patients

Original title:&nbsp;Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: Pooled Patient-Level Analysis From the HORIZONS-AMI and EUROMAX Trials.&nbsp;Reference:&nbsp;Stone GW et al. J Am CollCardiol. 2015 Jan 6;65(1):27-38. The HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) that included 3602 STEMI patients undergoing<a href="https://solaci.org/en/2015/01/29/net-clinical-benefit-of-bivalirudin-in-stemi-patients/" title="Read more" >...</a>

Percutaneous treatment of aortic coarctation with self-expandable uncovered nitinol stent

Original title:&nbsp;Percutaneous treatment of adult isthmic aortic coarctation: acute and long-term clinical and imaging outcome with a self-expandable uncovered nitinol stent.&nbsp;Reference:&nbsp;Kische S et al. Circ Cardiovasc Interv. 2015 Jan;8(1). &nbsp; The aim of this study was to show perioperative and long term results of the percutaneous treatment of aortic coarctation with the self-expandable uncovered nitinol<a href="https://solaci.org/en/2015/01/28/percutaneous-treatment-of-aortic-coarctation-with-self-expandable-uncovered-nitinol-stent/" title="Read more" >...</a>

Never ending controversy over the duration of post DES dual antiplatelet therapy

Original title:&nbsp;Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month &#8211; Dual Antiplatelet Therapy- The SECURITY Randomized Clinical Trial.&nbsp;Reference:&nbsp;Antonio Colombo et al. J Am CollCardiol. 2014 Nov 18;64(20):2086-97. The optimal duration of dual antiplatelet therapy after second-generation DES implantation is still debated and apparently will remain controversial for some time. The aim of this<a href="https://solaci.org/en/2015/01/15/never-ending-controversy-over-the-duration-of-post-des-dual-antiplatelet-therapy/" title="Read more" >...</a>

Risks and benefits of Dual Antiplatelet beyond the year of a drug-eluting stent

Original title: Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents.&nbsp;Reference: Laura Mauri et al. N Engl J Med 2014;371:2155-66. &nbsp; Dual antiplatelet therapy is recommended after a drug-eluting stent to prevent thrombotic complications. The clinical benefit of this scheme it is not clear beyond one year. Patients were registered to receive a<a href="https://solaci.org/en/2015/01/13/risks-and-benefits-of-dual-antiplatelet-beyond-the-year-of-a-drug-eluting-stent/" title="Read more" >...</a>

Hybrid Revascularization in Multiple Vessels

Original title:&nbsp;Hybrid Revascularization for Multivessel Coronary Artery Disease&nbsp;Reference:&nbsp;Mariuz Gassior, et al. J Am Cardiol Intv 2014;7:1277-83 &nbsp; According to the international guidelines, coronary artery bypass grafting (CABG) continues to be the &ldquo;Gold Standard&rdquo; treatment for multiple vessels diseases. However, second generation DES and the hybrid strategy may eventually change indications. &nbsp; This study randomized 102<a href="https://solaci.org/en/2014/12/18/hybrid-revascularization-in-multiple-vessels/" title="Read more" >...</a>

Lower Rates of In-Stent Thrombosis with the New Generation DES

Original title:&nbsp;New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction: a propensity-score-adjusted analysis from the multicenter REAL registry.&nbsp;Reference:&nbsp;Vignali L et al. Cath Cardiovasc Interv. 2014; Epub ahead of print. Compared to the first generation of drug eluting stents (DES), the new generation has a lower long term risk of in-stent thrombosis and acute myocardial infarction<a href="https://solaci.org/en/2014/10/30/lower-rates-of-in-stent-thrombosis-with-the-new-generation-des/" title="Read more" >...</a>

PCI Superior to Optimal Medical Treatment in Patients with Ischemic Cardiomyopathy

Original title:&nbsp;Fractional Flow Reserve&ndash;Guided PCI for Stable Coronary Artery Disease. The FAME 2 Trial Investigators.&nbsp;Reference:&nbsp;Bernard De Bruyne et al. N Engl J Med 2014;371:1208-17. The FAME 2 and the COURAGE studies tested similar hypothesis, only in the first study PCI was guided by fractional flow reserve (FFR) in addition to an angiography. The study hypothesis<a href="https://solaci.org/en/2014/10/29/pci-superior-to-optimal-medical-treatment-in-patients-with-ischemic-cardiomyopathy/" title="Read more" >...</a>

Hemodialysis Associated to Higher Incidence of In Stent Thrombosis

Original title:&nbsp;Impact of hemodialysis on local vessel healing and thrombus formation after drug-eluting stent implantation.&nbsp;Reference:&nbsp;Akihide Konishi, et al. &nbsp;Journal of Cardiology 2014;64:25-31 &nbsp; Even though the benefit of DES implantation to the general population is undeniable, it has been proved lower in hemodialysis patients (HD); the reason behind this phenomenon remains unclear. 121 patients received<a href="https://solaci.org/en/2014/08/08/hemodialysis-associated-to-higher-incidence-of-in-stent-thrombosis/" title="Read more" >...</a>

Proximal protection devices could be the first choice for most carotid artery stenting procedures

Original title:&nbsp;Evaluation of proximal protection devices during carotid artery stenting as the first choice for embolic protection.&nbsp;Reference:&nbsp;Hornung M et al. EuroIntervention. 2014; Epub ahead of print. This series of the Frankfurt CardioVascular Center included 124 consecutive patients undergoing carotid angioplasty with proximal protection. The first 92 patients received the Gore Flow Reversal System (WL Gore;<a href="https://solaci.org/en/2014/07/31/proximal-protection-devices-could-be-the-first-choice-for-most-carotid-artery-stenting-procedures/" title="Read more" >...</a>

Reduced risk of acute, late and very late thrombosis with new generations of DES versus BMS in the acute myocardial context

Original title:&nbsp;Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR.&nbsp;Reference:&nbsp;Sarno G et al. J Am Coll Cardiol. 2014;Epub ahead of print. This study evaluated 34147 consecutive patients suffering acute myocardial infarction with ST-segment elevation included in the SCAAR registry (Swedish Coronary Angiography and Angioplasty Registry) undergoing primary<a href="https://solaci.org/en/2014/07/11/reduced-risk-of-acute-late-and-very-late-thrombosis-with-new-generations-of-des-versus-bms-in-the-acute-myocardial-context/" title="Read more" >...</a>

Top